Page last updated: 2024-10-25

deferoxamine and Milk-Alkali Syndrome

deferoxamine has been researched along with Milk-Alkali Syndrome in 1 studies

Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Mudde, AH1
Roodvoets, AP1
Van Groningen, K1

Other Studies

1 other study available for deferoxamine and Milk-Alkali Syndrome

ArticleYear
Hypercalcaemic osteomalacia and encephalopathy due to aluminium intoxication in haemodialysis patients. Clinical aspects and treatment with desferrioxamine.
    The Netherlands journal of medicine, 1985, Volume: 28, Issue:1

    Topics: Aluminum Hydroxide; Brain Diseases; Deferoxamine; Female; Humans; Hypercalcemia; Male; Middle Aged;

1985